Neurology · HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Tropical Spastic Paraparesis (HAM/TSP): A Patient Guide

At a Glance

HAM/TSP is a chronic HTLV-1-associated inflammation of the spinal cord that can gradually worsen leg stiffness, weakness, bladder problems, and nerve pain. Although there is no cure, rehabilitation, symptom treatment, and coordinated care can help preserve function and independence.

HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) is a chronic, inflammatory condition of the spinal cord that develops in a small number of people carrying the Human T-cell Lymphotropic Virus Type 1 (HTLV-1). While the virus is more common in specific regions—including parts of Japan, the Caribbean, South America, and Africa—only about 0.5% to 5% of carriers will ever develop this neurological complication ^[1]^[2]. The condition is not caused by the virus directly killing nerve cells, but rather by an overactive immune response that causes “bystander damage” to the spinal cord, leading to scarring and interference with the signals traveling to the lower body ^[3].

The hallmark of the disease is a slow, progressive stiffness and weakness in the legs, a combination known as spastic paraparesis. This often begins as a subtle change in gait or a feeling of “heaviness” when walking, and it is frequently accompanied by significant bladder dysfunction and neuropathic pain ^[4]^[5]. Because the inflammation is concentrated in the middle and lower sections of the spinal cord, the upper body, hands, and cognitive functions—such as memory and thinking—are usually preserved ^[6]. However, any new symptoms in your arms or cognition should be evaluated by a doctor. For most patients, the journey toward a diagnosis is long, but identifying the condition is the first step toward a proactive management plan.

While there is currently no cure for HAM/TSP, the focus of modern care is on preserving independence and managing symptoms effectively. Treatment often involves a combination of symptom management and specialized physical rehabilitation to maintain muscle function. Physical therapy and supervised exercise programs have been shown in small studies to improve balance and core strength, helping patients navigate physical changes with more confidence ^[7]. For some patients with progressive disease, off-label medications like corticosteroids may be considered to try and slow the immune system’s attack, though evidence remains limited ^[8]^[9].

Living with HAM/TSP requires a dedicated, multidisciplinary care team and a long-term commitment to health. By tracking your mobility and staying ahead of symptoms like bladder urgency or nerve pain, you can play an active role in your own care. This guide is designed to empower you with the evidence-based information you need to navigate these conversations with your doctors and build a life that prioritizes your function and well-being ^[10]^[11].

In this guide

6 chapters

Understanding Your Diagnosis of Tropical Spastic Paraparesis (HAM/TSP)

Understand a HAM/TSP diagnosis, including HTLV-1 transmission, spinal cord damage, expected symptoms, ATL differences, and urgent warning signs to watch for.

Symptoms and the Daily Impact of HAM/TSP

Learn about HAM/TSP (tropical spastic paraparesis): leg stiffness, balance changes, bladder and bowel symptoms, pain, daily fluctuations, and progression.

Diagnostic Criteria and Lab Results for HAM/TSP

Learn how HAM/TSP is diagnosed, including HTLV-1 blood tests, CSF findings, MRI scans, formal criteria, and tests used to rule out other similar conditions.

Medical Treatments and Investigational Therapies for HAM/TSP

Learn about HAM/TSP treatment, including corticosteroids, steroid safety, investigational drugs, clinical trials, and why ARVs do not treat HAM/TSP alone.

Symptom Management and Physical Rehabilitation

Learn how HAM/TSP symptom management can reduce spasticity, pain, bladder problems, and falls through rehabilitation, medication, and safety planning.

Long-Term Monitoring and Building Your Care Team

Learn how HAM/TSP monitoring tracks mobility, bladder health, symptoms, and inflammation, and how a multidisciplinary care team supports long-term independence.

Common questions in this guide

What is HAM/TSP, and what causes it?

HAM/TSP is a chronic inflammatory condition of the spinal cord that can occur in a small number of people who carry HTLV-1. The spinal cord injury is believed to result mainly from an overactive immune response rather than the virus directly killing nerve cells.

What symptoms are common with HAM/TSP?

Common symptoms include gradually worsening leg stiffness and weakness, changes in walking, a heavy feeling in the legs, bladder problems, and nerve pain. The upper body and thinking abilities are usually preserved, but new arm or cognitive symptoms should be evaluated by a doctor.

Is there a cure for HAM/TSP?

There is currently no cure for HAM/TSP. Treatment focuses on managing symptoms, preserving mobility and independence, and coordinating long-term care among specialists.

Can physical therapy help people with HAM/TSP?

Physical therapy and supervised exercise may help maintain muscle function, balance, and core strength. A rehabilitation professional can tailor activities to your abilities and help you exercise safely as symptoms change.

Can medication slow the progression of HAM/TSP?

For some people with progressive HAM/TSP, a doctor may consider corticosteroids to reduce immune activity. These medicines are used off-label in this setting, and evidence of benefit is limited, so the possible benefits and risks should be discussed with a specialist.

What can I do to preserve my ability to walk with HAM/TSP?

Work with a rehabilitation team on an individualized physical therapy and exercise plan, and track changes in walking, balance, bladder function, and pain. Reporting changes early can help your care team adjust symptom treatment and support your independence.

Curated prompts to bring to your next appointment.

1.Based on my current symptoms, am I considered to have a 'slow' or 'rapidly' progressive form of HAM/TSP?
2.What is the most important thing I can do right now to preserve my ability to walk for as long as possible?
3.Who will be the primary point of contact on my care team to coordinate between my neurologist and urologist?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References (11)

1
Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.
Legrand N, McGregor S, Bull R, et al.
Clinical microbiology reviews 2022; (35(2)):e0007821 doi:10.1128/cmr.00078-21.
PMID: 35195446
2
Immunopathogenesis and Cellular Interactions in Human T-Cell Leukemia Virus Type 1 Associated Myelopathy/Tropical Spastic Paraparesis.
Aghajanian S, Teymoori-Rad M, Molaverdi G, Mozhgani SH
Frontiers in microbiology 2020; (11()):614940 doi:10.3389/fmicb.2020.614940.
PMID: 33414779
3
Role of Integrin Signaling Activation on the Development of Human T Cell Leukemia Virus-1 (HTLV-1)-Associated Myelopathy/Tropical Spastic Paraparesis: Its Relationship to HTLV-1-Infected CD4+ T Cell Transmigrating Activity into the Tissues.
Nakamura T, Satoh K, Nakamura H, et al.
AIDS research and human retroviruses 2018; (34(4)):331-336 doi:10.1089/AID.2017.0261.
PMID: 29400072
4
Neuroimmunology of Human T-Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis.
Nozuma S, Jacobson S
Frontiers in microbiology 2019; (10()):885 doi:10.3389/fmicb.2019.00885.
PMID: 31105674
5
Urodynamic findings and vibegron effects on neurogenic lower urinary tract dysfunction caused by human T-cell leukemia virus type I-associated myelopathy/tropical spastic paraparesis.
Kumekawa T, Akaihata H, Natsuya H, et al.
IJU case reports 2024; (7(6)):438-441 doi:10.1002/iju5.12773.
PMID: 39498183
6
Association Between HTLV-1 Genotypes and Risk of HAM/TSP.
Saito M
Frontiers in microbiology 2019; (10()):1101 doi:10.3389/fmicb.2019.01101.
PMID: 31156605
7
Pilates exercise improves the clinical and immunological profiles of patients with human T-cell lymphotropic virus 1 associated myelopathy: A pilot study.
Klautau AV, da Silva Pinto D, Santana BB, et al.
Journal of bodywork and movement therapies 2020; (24(3)):1-8 doi:10.1016/j.jbmt.2020.02.012.
PMID: 32825975
8
Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy.
Mashkani B, Jalili Nik M, Rezaee SA, Boostani R
Expert review of neurotherapeutics 2023; (23(12)):1233-1248 doi:10.1080/14737175.2023.2272639.
PMID: 37933802
9
Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy.
Buell KG, Puri A, Demontis MA, et al.
PloS one 2016; (11(4)):e0152557 doi:10.1371/journal.pone.0152557.
PMID: 27077747
10
Health state utility values in people living with HTLV-1 and in patients with HAM/TSP: The impact of a neglected disease on the quality of life.
Rosadas C, Assone T, Yamashita M, et al.
PLoS neglected tropical diseases 2020; (14(10)):e0008761 doi:10.1371/journal.pntd.0008761.
PMID: 33064742
11
Targeted Interventions in HAM/TSP: Emerging Therapies and Future Directions - A Narrative Review.
Rezaei MM, Nia MK, Rouzbahani KA, et al.
Health science reports 2026; (9(8)):e72863 doi:10.1002/hsr2.72863.
PMID: 42534713

This HAM/TSP page is for informational purposes only and does not constitute medical advice. Talk with your neurologist, urologist, and rehabilitation team about symptoms, treatment choices, and changes in mobility or bladder function.

Get notified when new evidence is published on Tropical spastic paraparesis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents